DOCSLIB.ORG

2019 Annual Meeting Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2019 Annual Meeting Program WWW.HISTIOCYTESOCIETY.ORG 2 HISTIOCYTE SOCIETY ANNUAL MEETING 2019 TABLE OF CONTENTS WELCOME TO MEMPHIS ...................................................................................................................................................................... 5 ABOUT THE HISTIOCYTE SOCIETY .................................................................................................................................................... 6 2019 ANNUAL MEETING MOBILE APP ............................................................................................................................................... 6 ANNUAL MEETING PROGRAM ............................................................................................................................................................ 6 HISTIOCYTOSIS ASSOCIATION AND HISTIOCYTE SOCIETY .......................................................................................................... 7 ACKNOWLEDGEMENTS AND RECOGNITIONS ................................................................................................................................. 8 MARLO THOMAS GLOBAL EDUCATION CENTER FLOOR PLAN .................................................................................................. 10 AT-A-GLANCE MEETING AGENDA ................................................................................................................................................... 11 GUEST SPEAKER HIGHLIGHTS ........................................................................................................................................................ 13 MEET THE EXPERTS PRESENTER HIGHLIGHTS ........................................................................................................................... 15 EDUCATION SESSIONS PRESENTER HIGHLIGHTS ....................................................................................................................... 16 MEETING AGENDA ............................................................................................................................................................................. 18 POSTER LOCATION MAP ................................................................................................................................................................... 31 GUEST SPEAKER PRESENTATIONS ................................................................................................................................................ 34 SCIENTIFIC SESSION I ABSTRACTS ................................................................................................................................................ 38 SCIENTIFIC SESSION II: PRESIDENTIAL SYMPOSIUM ABSTRACTS ........................................................................................... 40 POSTER PRESENTATION SESSION ABSTRACTS .......................................................................................................................... 43 SCIENTIFIC SESSION III ABSTRACTS .............................................................................................................................................. 69 NESBIT PRIZE IN CLINICAL SCIENCE .............................................................................................................................................. 71 NEZELOF PRIZE IN BASIC SCIENCE ................................................................................................................................................ 71 ROBERT J. ARCECI PRIZE FOR BEST POSTER .............................................................................................................................. 72 HISTIOCYTE SOCIETY GOVERNING BY-LAWS ............................................................................................................................... 73 HISTIOCYTE SOCIETY CONSTITUTION ............................................................................................................................................ 76 PRESENTING AUTHOR INDEX .......................................................................................................................................................... 77 2020 ANNUAL MEETING ANNOUNCEMENT ..................................................................................................................................... 86 MEETING SPONSORS WWW.HISTIOCYTESOCIETY.ORG 3 www.cincinnatichildrens.org/DIL 4 HISTIOCYTE SOCIETY ANNUAL MEETING 2019 WELCOME TO MEMPHIS Dear Colleagues, The Histiocyte Society cordially welcomes you to the 35th Annual Meeting, which will be held in Memphis, TN, on November 3rd, 4th and 5th, 2019 and hosted by the world’s famous St. Jude Children’s Research Hospital. Founded by the entertainer Danny Thomas and opened in 1962, St. Jude has made a tremendous development over the past six decades. It is a place to go for any pediatric hem/onc where one can learn not only about the most recent developments in the field but also how to perform professional fundraising and how international outreach programs can improve children’s fates and save lives in remote countries. Memphis itself is not just a city; it is the birthplace and a contemporary witness of the civil rights movement. Downtown Memphis is home to the National Civil Rights Museum at the Lorraine Motel, the site of Dr. Martin Luther King’s assassination. Last year the 50th anniversary of this event has been celebrated and as a result, there are now several new memorials not far from the NCRM. Memphis is also rich in musical history. It is Home of Blues, Soul and Rock 'n' Roll. While Graceland is the obvious stop for Elvis fans, there are also a number of live music hot spots for those who like to obtain a personal feeling of the musical flavor of Memphis. This year our Program Committee was supported by local organizers from the St. Jude staff to prepare an attractive meeting agenda. We have invited Prof. Miriam Merad, a renowned expert on dendritic cell biology to share her new research and its implications for the histiocytic disorders. The traditional Jon Pritchard lecture on Nikolas Symposium this year is dedicated to immune strategies in histiocytosis. The meeting will be rounded up by two thematic symposia on LCH and HLH, as well as by the scientific and meet-the-expert-sessions. This year the transition of the presidency is due and Michael Jordan from Cincinnati will take over for the next three years. The social highlights of our meetings are as usual the Welcome Reception and the Annual Banquet. The Welcome Reception will take place in the Skyway Ballroom and open-air rooftop at the historic Peabody Hotel. Enjoy a casual evening of networking and refreshments all while enjoying a special performance by Memphis' own Stax Music Academy. The Annual Banquet, always a highlight of the meeting, will take place in Elvis' Car Museum on the grounds of Elvis' famous Graceland. Tours of the mansion will be provided before making our way to the car museum to enjoy dinner and dancing to the sounds of the St. Jude Band. As you know, meeting of this format require a lot of time, energy and resources to be properly organized. I would like to specially appreciate our symbiotic partner and key sponsor, the Histiocytosis Association, without whose generous support this meeting would not be possible. I look forward to seeing you in Memphis! Welcome to the Histiocyte Society Meeting 2019! Milen Minkov President Histiocyte Society WWW.HISTIOCYTESOCIETY.ORG 5 ABOUT THE HISTIOCYTE SOCIETY The Histiocyte Society is a professional medical association comprised of more than 200 physicians and scientists from around the world. Members of the organization are considered to be the leaders in understanding and treating histiocytic disorders. The Society is committed to advancing knowledge about histiocytic disorders and improving outcomes for patients through the planning, development, sponsorship and oversight of clinical research. Building Knowledge The Histiocyte Society hosts an annual scientific meeting in different locations around the world. Attendance is open to members of the Society as well as other professionals working in the field of histiocytic disorders and related studies. Meetings feature presentations of individual and collective research efforts as well as keynote lectures from guest speakers; special-interest groups convene to discuss and develop new and innovative treatment regimes. This interactive forum allows the best and brightest minds in the histiocytosis community to share the most progressive information and to shape the future of research. Beyond the prolific exchanges that occur during the meeting, presenters work collectively to extend their reach by publishing subsequent articles and manuscripts in scientific journals worldwide. Advancing Treatment Through extensive research and collaboration, the Histiocyte Society has made numerous, significant strides in the fight against histiocytic disorders. The Society has established scientific standards for histiocytic disorders that are accepted worldwide; they include: 1) A common language of uniform disease classification, 2) Standardized diagnostic criteria, and 3) Guidelines for patient evaluation and follow-up. The Society remains dedicated to facilitating essential and innovative clinical research – developing critical knowledge and increasingly effective treatments in the pursuit of a cure. 2019 ANNUAL MEETING MOBILE APP - INVITATION IN YOUR EMAIL The 2019 Histiocyte
Load more

Recommended publications
  • FT117 Langerhans Cell Histiocytosis with Histopathological Features
    FT117 Langerhans cell histiocytosis with histopathological features, single center experience Histopatolojik özellikleriyle langerhans hücreli histiyositoz, tek merkez deneyimi Fahriye KILINÇ Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi, Tıbbi Patoloji Anabilim Dalı, Konya Aim: Langerhans cell histiocytosis (LCH) is a rare histiocytic disease, occurring in 2-10 children per million and 1-2 adults per million, and may have a wide variety of clinical manifestations. Infiltration can develop in almost any organ (the most commonly reported organs are bone, skin, lymph nodes, lungs, thymus, liver, spleen, bone marrow and central nervous system). We aimed to evaluate the histopathological features of the lesions and review the literature in pediatric patients referred to our department for pathological examination and diagnosed as LCH. Materials and Methods: Retrospectively, childhood cases diagnosed with LCH in 2012-2019 were screened by hospital automation system. Age, gender, lesion localizations of the cases were recorded and histopathological features were reviewed. Results: 5 male and 5 female total of 10 cases were detected. The youngest 3 were under the age of 1, the oldest was 16 years old. Localization; 6 of the cases were bone (2 femur, 3 skull bone, 1 scapula), 2 skin, 1 bone and lymph node, 1 lung and lymph node. Histopathology revealed histiocytic cells with grooved nuclei, eosinophilic cytoplasm with eosinophils, and neutrophils in some cases. Immunohistochemical CD1a staining was positive in all cases and positivities were present with S100 in applied 9 cases, CD68 in 4. Ki67 proliferation index was studied in 2 patients with bone localization, 15% and 20%. Conclusion: The term LCH is due to the morphological and immunophenotypic similarity of the infiltrating cells of this disease to Langerhans cells specialized as dendritic cells in the skin and mucous membranes.
    [Show full text]
  • Skin Biopsy Diagnosis of Langerhans Cell Neoplasms
    Chapter 3 Skin Biopsy Diagnosis of Langerhans Cell Neoplasms Olga L. Bohn, Julie Teruya-Feldstein and Sergio Sanchez-Sosa Additional information is available at the end of the chapter http://dx.doi.org/10.5772/55893 1. Introduction This chapter reviews the clinical presentation, histopathology, immunoprofile and molecular features of Langerhans cell neoplasms of the skin including Langerhans cell histiocytosis (LCH) and its malignant counterpart, Langerhans cell sarcoma (LCS). Biopsy of the skin is a useful method to confirm LCH/LCS diagnosis, as cutaneous involvement is seen in more than 50% cases. Skin can be the only presenting site of LCH, but it is usually seen as an integral part of multisystemic disease involvement. Langerhans cells (LC) are bone marrow-derived antigen presenting cells [1]. Although LC, dendritic cells and monocytic/histiocytic cells share a common multipotential progenitor cells that reside in the bone marrow, to the date, myeloid derived macrophages and dendritic cells constitute divergent lines of differentiation from bone marrow precursors [2]. However, recent evidence demonstrates that LC can be generated from lymphoid-committed CD4low precur‐ sors, suggesting the role of lineage plasticity/ trans-differentiation and clonal infidelity [3-4]. LC can be found in the epidermis and mucosal lining of multiple organs including cervix, vagina, stomach and esophagus. The specific immunophenotypic profile is helpful distin‐ guishing LCs, as they can express CD1a and langerin (CD207); in addition the detection of Birbeck granules, seen in both pathological and resting LC is a prominent feature [5]. LCH encompasses a spectrum of disease characterized by an uncontrolled proliferation of LC [5].
    [Show full text]
  • Histiocytic and Dendritic Cell Lesions
    1/18/2019 Histiocytic and Dendritic Cell Lesions L. Jeffrey Medeiros, MD MD Anderson Cancer Center Outline 2016 classification of Histiocyte Society Langerhans cell histiocytosis / sarcoma Erdheim-Chester disease Juvenile xanthogranuloma Malignant histiocytosis Histiocytic sarcoma Interdigitating dendritic cell sarcoma Follicular dendritic cell sarcoma Rosai-Dorfman disease Hemophagocytic lymphohistiocytosis Writing Group of the Histiocyte Society 1 1/18/2019 Major Groups of Histiocytic Lesions Group Name L Langerhans-related C Cutaneous and mucocutaneous M Malignant histiocytosis R Rosai-Dorfman disease H Hemophagocytic lymphohistiocytosis Blood 127: 2672, 2016 L Group Langerhans cell histiocytosis Indeterminate cell tumor Erdheim-Chester disease S100 Normal Langerhans cells Langerhans Cell Histiocytosis “Old” Terminology Eosinophilic granuloma Single lesion of bone, LN, or skin Hand-Schuller-Christian disease Lytic lesions of skull, exopthalmos, and diabetes insipidus Sidney Farber Letterer-Siwe disease 1903-1973 Widespread visceral disease involving liver, spleen, bone marrow, and other sites Histiocytosis X Umbrella term proposed by Sidney Farber and then Lichtenstein in 1953 Louis Lichtenstein 1906-1977 2 1/18/2019 Langerhans Cell Histiocytosis Incidence and Disease Distribution Incidence Children: 5-9 x 106 Adults: 1 x 106 Sites of Disease Poor Prognosis Bones 80% Skin 30% Liver Pituitary gland 25% Spleen Liver 15% Bone marrow Spleen 15% Bone Marrow 15% High-risk organs Lymph nodes 10% CNS <5% Blood 127: 2672, 2016 N Engl J Med
    [Show full text]
  • Cutaneous Neonatal Langerhans Cell Histiocytosis
    F1000Research 2019, 8:13 Last updated: 18 SEP 2019 SYSTEMATIC REVIEW Cutaneous neonatal Langerhans cell histiocytosis: a systematic review of case reports [version 1; peer review: 1 approved with reservations, 1 not approved] Victoria Venning 1, Evelyn Yhao2,3, Elizabeth Huynh2,3, John W. Frew 2,4 1Prince of Wales Hospital, Randwick, Sydney, NSW, 2033, Australia 2University of New South Wales, Sydney, NSW, 2033, Australia 3Sydney Children's Hospital, Randwick, NSW, 2033, Australia 4Department of Dermatology, Liverpool Hospital, Sydney, Sydney, NSW, 2170, Australia First published: 03 Jan 2019, 8:13 ( Open Peer Review v1 https://doi.org/10.12688/f1000research.17664.1) Latest published: 03 Jan 2019, 8:13 ( https://doi.org/10.12688/f1000research.17664.1) Reviewer Status Abstract Invited Reviewers Background: Cutaneous langerhans cell histiocytosis (LCH) is a rare 1 2 disorder characterized by proliferation of cells with phenotypical characteristics of Langerhans cells. Although some cases spontaneously version 1 resolve, no consistent variables have been identified that predict which published report report cases will manifest with systemic disease later in childhood. 03 Jan 2019 Methods: A systematic review (Pubmed, Embase, Cochrane database and all published abstracts from 1946-2018) was undertaken to collate all reported cases of cutaneous LCH in the international literature. This study 1 Jolie Krooks , Florida Atlantic University, was registered with PROSPERO (CRD42016051952). Descriptive statistics Boca Raton, USA and correlation analyses were undertaken. Bias was analyzed according to Milen Minkov , Teaching Hospital of the GRADE criteria. Medical University of Vienna, Vienna, Austria Results: A total of 83 articles encompassing 128 cases of cutaneous LCH were identified.
    [Show full text]
  • Beyond Langerhans Cell Histiocytosis Related to Smoking
    Radiología. 2019;61(3):215---224 www.elsevier.es/rx RADIOLOGY THROUGH IMAGES Pulmonary histiocytosis: Beyond Langerhans cell ଝ histiocytosis related to smoking a b a c d b,e,∗ C. Trejo Gallego , J. Bueno , E. Cruces , E.B. Stelow , N. Mancheno˜ , L. Flors a Servicio de Radiología, Hospital Universitario Morales Meseguer, Universidad de Murcia, Murcia, Spain b Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, VA, United States c Department of Pathology, University of Virginia Health System, Charlottesville, VA, United States d Servicio de Anatomía Patológica, Hospital Universitario y Politécnico la Fe, Valencia, Spain e Department of Radiology, One Hospital Dr, University of Missouri Health System, Columbia, MO, United States Received 21 October 2017; accepted 16 November 2018 Available online 24 January 2019 KEYWORDS Abstract Langerhans cells Objective: To review the imaging findings for the different types of pulmonary histiocy- histiocytosis; tosis. In particular, in addition to the well-known pulmonary Langerhans cell histiocytosis Erdheim---Chester related to smoking and its possible appearance in nonsmokers, we focus on non-Langerhans disease; cell histiocytosis in Rosai---Dorfman disease and Erdheim---Chester disease. We also review the Sinus histiocytosis; etiopathogenesis, histology, clinical presentation, and treatment of pulmonary histiocytosis. Computed Conclusion: Langerhans cell histiocytosis, Rosai---Dorfman disease, and Erdheim---Chester dis- tomography ease are idiopathic
    [Show full text]
  • Histiocytic Sarcoma in a 3-Year-Old Male: a Case Report
    Histiocytic Sarcoma in a 3-Year-Old Male: A Case Report Samuel Buonocore, MD*; Alfredo L. Valente, MD‡; Daniel Nightingale, MD‡; Jeffrey Bogart, MD§; and Abdul-Kader Souid, MD, PhD* ABSTRACT. We describe a pediatric patient with his- CASE REPORT tiocytic sarcoma involving the T6 and L4 vertebral bodies This previously healthy 3-year-old boy experienced intermit- and the lungs. His tumor progressed during chemother- tent low back pain radiating to the right inguinal region for ϳ2 apy designed for Langerhans’ cell histiocytosis and sar- months. His symptoms initially responded to ibuprofen. The pain coma. High-dose radiation, on the other hand, was intensity increased over a 2-week period, and he refused to walk. effective. Pediatrics 2005;116:e322–e325. URL: www. Review of systems was significant for pain with urination. With the exception of being unable to stand, his physical examination pediatrics.org/cgi/doi/10.1542/peds.2005-0026; sarcoma, was unremarkable. The laboratory tests showed normal blood histiocytes, Langerhans’ cell histiocytosis, histiocytic sar- counts and normal liver and renal function. An MRI showed coma. collapse of the T6 and L4 vertebral bodies and a soft tissue mass in the anterior epidural space at the level of L4 (Fig 1 A and B). The chest and abdominal computed tomography (CT) scans were nor- ABBREVIATIONS. LCH, Langerhans’ cell histiocytosis; CT, com- mal. Bone marrow aspiration revealed no malignant infiltration. A puted tomography; 2CdA, 2-chlorodeoxyadenosine. technetium bone scan showed increased uptake limited to the T6 and L4 regions. CT-scan–guided needle biopsy of the L4 mass revealed infiltrative proliferation of the bone and soft tissue by istiocytic and dendritic neoplasms are rare, sheets and clusters of large ovoid cells with abundant eosinophilic cytoplasm (Fig 2A).
    [Show full text]
  • Langerhans Cell Sarcoma with an Aberrant Cytoplasmic CD3 Expression Zhaodong Xu1*, Ruth Padmore1, Carolyn Faught2, Lisa Duffet2 and Bruce F Burns3
    Xu et al. Diagnostic Pathology 2012, 7:128 http://www.diagnosticpathology.org/content/7/1/128 CASE REPORT Open Access Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression Zhaodong Xu1*, Ruth Padmore1, Carolyn Faught2, Lisa Duffet2 and Bruce F Burns3 Abstract: Langerhans cell sarcoma is a rare and aggressive high grade hematopoietic neoplasm with a dismal prognosis. It has a unique morphological and immunotypic profile with a CD1a/ langerin/S100 + phenotype. T cell lineage markers except for CD4 in Langerhans cell sarcoma have not been documented previously. We report a case of 86 year-old male of Caucasian descent who presented with an enlarging right neck mass over 2 months with an underlying unknown cause of anemia. Computed tomography scan of the neck, chest and abdomen revealed generalized lymphadenopathy and mild splenomegaly suspicious for lymphoma. Diagnostic core biopsy performed on right neck mass revealed a possible T cell lymphoma with expression of T cell lineage specific marker CD3 but conclusive diagnosis could not be made due to insufficient core biopsy sample. Further excisional biopsy performed on a left inguinal node showed a hematopoietic neoplasm with features of Langerhans cell sarcoma with a focal cytoplasmic CD3 expression in 30-40% of the tumor cells. PCR for T cell receptor (TCR) gene rearrangement failed to demonstrate a clonal gene rearrangement in the tumor cells arguing against a T cell lineage transdifferentiation, suggesting an aberrant CD3 expression. To the best of our knowledge, this case represents the first report of Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression. Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/2065486371761991 Keywords: Langerhans cell sarcoma (LCS), Langerhans cell histiocytosis (LCH), CD3, Aberrant expression, Lineage plasticity, Transdifferentiation Background langerin/S100+ [2,3] but without B- and T-cell lineage According to the most recent WHO Classification of markers except for CD4 [4].
    [Show full text]
  • Histiocytic Sarcoma Originating in the Lung in a 16-Year-Old Male
    J Clin Exp Hematop Vol. 55, No. 1, June 2015 Case Study Histiocytic Sarcoma Originating in the Lung in a 16-Year-Old Male Sakura Tomita,1) Go Ogura,1) Chie Inomoto,1) Hiroshi Kajiwara,1) Ryota Masuda,2) Masayuki Iwazaki,2) Masaru Kojima,3) and Naoya Nakamura1) We report a 16-year-old male with histiocytic sarcoma (HS) originating in the lung. Partial resection of the lung was performed for a 3-cm mass with a clear boundary detected in the right inferior pulmonary lobe on a health checkup. Histologically, the tumor infiltrated into the surrounding tissue, and was comprised of spindle cells, mainly, and foam cells accompanied by mild nuclear atypia. The tumor cells were immunohistochemically positive for CD68 and CD163, indicating histiocytic lineage and the MIB-1-positive rate was low. Spindle cell morphology of HS is quite rare and only 3 cases of pulmonary HS have previously been reported. 〔J Clin Exp Hematop 55(1) : 45-49, 2015〕 Keywords: histiocytic sarcoma, lung, spindle cells, foamy cells spindle cells, mainly, and foam cells. INTRODUCTION Histiocytic sarcoma (HS) is a malignant hematopoietic CASE REPORT tumor consisting of cells similar to mature histiocytes.1-4 It is extremely rare and the age of onset widely ranges from 6 The patient was a 16-year-old male who exhibited an months to 89 years, with no gender difference; the incidence abnormal shadow detected on a health checkup. He had no is high in adults, showing a large peak at 50-69 years, but also particular past or familial medical history.
    [Show full text]
  • Langerhans Cell Histiocytosis
    2020 Virtual Pathology Course 08/22/2020 Saja Asakrah, MD PhD Assistant professor Hematopathologist Saja Asakrah, MD Ph.D Disclosure • No conflict of interest to disclose Case #13 A 44 year old male with no past medical history presented with a painless slowly growing lump in front of his left ear that he noticed one year prior. Histiocytes Cell of origin and classification Reactive versus clonal/neoplastic histiocytic infiltrate Malignant histiocytic infiltrate (sarcoma) Associated with hematopoietic or non hematopoietic lesions Classic morphology of Langerhans cell histioyocytosis involving a lymph node CD1a Langerin S100 HLA-DR A case of Erdheim-Chester disease involving tibia Histiocytes Cell of origin and classification Reactive versus clonal/neoplastic histiocytic infiltrate Malignant histiocytic infiltrate (sarcoma) Associated with hematopoietic or non hematopoietic lesions Dermatopathic lymphadenopathy In: Atlas of Lymph Node Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7959-8_31 Reactive histiocytosis in a left neck mass core biopsy CD1a Cytokeratin AE1/AE3 Dx Nasopharyngeal carcinoma EBV ISH In challenging cases mutational analysis may be helpful in supporting a clonal process REVIEW Volume 23 Number 4 July 2016 MAPK pathway mutations • B-Raf proto-oncogen: In contrast to recurrent BRAF V600E mutations, other mutations in BRAF have been found only rarely in histiocytoses. These include BRAF V600D and BRAF V600insDLAT in LCH, BRAF F595L in histiocytic sarcoma • A-Raf Proto-oncogen: Recurrent in non-LCH and are present in 21% of ECD. • RAS isoforms: This includes NRAS mutations in 3–7% of ECD and less frequently in LCH.
    [Show full text]
  • Multifocal Langerhans Cell Sarcoma Involving Epidermis: a Case Report and Review Changsong Wang1*, Yanping Chen1, Chunfang Gao1, Jian Yin1 and Hong Li2
    Wang et al. Diagnostic Pathology 2012, 7:99 http://www.diagnosticpathology.org/content/7/1/99 CASE REPORT Open Access Multifocal Langerhans cell sarcoma involving epidermis: a case report and review Changsong Wang1*, Yanping Chen1, Chunfang Gao1, Jian Yin1 and Hong Li2 Abstract Objective: To study the clinico-pathological characteristics of Langerhans cell sarcoma (LCS) which involving epidermis. Methods: A case of primary multifocal LCS was analyzed in histopathology and immunophenotype. Results: A 41-year-old man with multifocal cutaneous LCS involving the inguina and waist was reported. Clinical and pathology data were available. Neoplastic cells with markedly malignant cytological features were observed. Tumor cells exhibited irregular shape with abundant and eosinophilic red staining cytoplasm; large, irregular-shaped, showing lobulated or dented nucleus and some cells with a longitudinal nuclear groove and prominent nucleoli. The tumor cells expressed CD1a, Langerin (CD207), S-100 protein, CD68 and vimentin, and did not express pan-T or B cell markers and epithelial markers. The patient died less than 1 year after diagnosis due to local recurrence and metastasis to the lung, despite the administration of local radiation and chemotherapy. Conclusions: LCS is a tumor with markedly malignant cytological features that originates from Langerhans cells. Primary multifocal neoplasms involving epidermis is even rare. Accurate diagnosis is based on the histopathological and immunohistochemical of the tumor cells. Virtual slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/ 1182345104754765. Keywords: Langerhans cell sarcoma, Multiple focus, Langerin, CD1a Background LCH is difficult. LCS occure at any age and involve The Langerhans cell tumors were classified into Langer- many organs or tissues, such as bone, lung, lymph hans cell histiocytosis (LCH) and Langerhans cell sar- nodes, liver and soft tissues.
    [Show full text]
  • Rosai–Dorfman Disease: Tumor Biology, Clinical Features
    A high degree of clinical suspicion is needed to diagnose Rosai–Dorman disease. Eight-Spotted Skimmer. Photograph courtesy of Sherri Damlo. www.damloedits.com. Rosai–Dorfman Disease: Tumor Biology, Clinical Features, Pathology, and Treatment Samir Dalia, MD, Elizabeth Sagatys, MD, Lubomir Sokol, MD, PhD, and Timothy Kubal, MD Background: Rosai–Dorfman disease (RDD) is a rare, nonmalignant clinical entity characterized by a group of clinical symptoms and characteristic pathological features. Methods: Articles that reviewed tumor biology, clinical features, pathology, and treatment for RDD were identified in a search of the literature for the years 1990 to 2014. The results from this body of literature were reviewed and summarized. Results: Patients with RDD generally present with massive, painless cervical lymphadenopathy, fevers, and elevated inflammatory markers. Extranodal disease is typical, with the most common sites being the skin and the central nervous system. Rarely, the gastrointestinal tract is involved. Immunohistochemistry remains the mainstay of diagnosis with S100 and CD68 positive cells while CD1a will be negative of involved histiocytes. Histologically, the disease shows the classical characteristic finding of emperipolesis. Many patients do not require treatment; however, surgical resection remains the mainstay of treatment for symptomatic disease. The role of steroids, chemotherapy, and radiation therapy continue to be based on small case series and case reports. Conclusions: RDD has a variable clinical presentation; therefore, a high degree of suspicion and a thorough pathological review are necessary to diagnose this rare clinical entity. Although some patients will experience spontaneous resolution, others may require surgical resection or steroid therapy and radiation or chemother- apy. Given the rarity of the disease and the lack of a clear therapeutic pathway, referring patients to a tertiary center is recommended for confirming the diagnosis and treatment considerations.
    [Show full text]
  • Extra Nodal Rosai Dorfman Disease of Nasal Septal Mucosa Without Lymphadenopathy
    Journal of Pathology of Nepal (2016) Vol. 6, 968 - 970 Journal of cal Patholo lini gis f C t o o f N n e io p t a a l i - c 2 PATHOLOGY o 0 s 1 s 0 A N u e d p n of Nepal a l a M m e h d t i a c K al , A ad ss o oc n R www.acpnepal.com iatio bitio n Building Exhi Case Report Extra nodal Rosai Dorfman disease of nasal septal mucosa without lymphadenopathy Raje P1, Vyas P1 1Department of Surgical Pathology and Cytology, Bombay Hospital Indore – Indore, India. ABSTRACT Keywords: Nasal septum; Rosai–Dorman disease, also known as sinus histiocytosis with massive lymphadenopathy, typically Rosai–Dorman disease; presents as massive enlargement of lymph nodes accompanied by systemic symptoms. Extranodal Lymphadenopathy involvement is also known usually in head and neck regions. Rarely the disease presents at extranodal sites only without involvement of lymph nodes. We present a case of 58 years-old female who presented with mass in nasal septum without involvement of lymph nodes. The mass was removed surgically and diagnosis was made on histological grounds with classical indings of histiocytic proliferation and emperipolesis. INTRODUCTION Rosai–Dorman disease (RDD), also known as sinus In 43% cases disease may have extra nodal involvement4, histiocytosis with massive lymphadenopathy (SHML), most common sites being nasal cavities, skin, eyes, orbit, a rare and usually self limiting disease, was originally eyelids, bones, soft tissue, the central nervous system, upper described by Destombes in 1965.1 Subsequently; in 1969, it respiratory tract
    [Show full text]